Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ: VTRS )

8.980 -0.260 (-2.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
September 2022 Stock Considerations
Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago. 
Via Talk Markets
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,... 
Via MarketBeat
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 529 companies set new 52-week lows. 
Via Benzinga
Viatris: Q2 Earnings Insights
  Viatris (NASDAQ:VTRS) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Expert Ratings for Viatris
Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter: 
Via Benzinga
This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems
From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle. 
Via Benzinga
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus
Via Benzinga
Recap: Viatris Q1 Earnings
Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label
Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is  
Via Benzinga
Earnings Scheduled For August 8, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
High Dividend 50: Viatris
Viatris is currently offering an above-average dividend yield of 4.4%. The company has posted GAAP losses in each of the last two years but its payout ratio is only 13% using adjusted EPS. 
Via Talk Markets
7 High-Quality Dividend Stocks With High Yields
These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments. 
Via InvestorPlace
Looking Into Viatris's Return On Capital Employed
According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4. 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
Current Report: Viatris
Viatris Inc’s price per share was $11.68 as of yesterday's market close. One year ago its price was $15.59. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
Upgrades 
Via Benzinga
3 Top S&P 500 Stock Market Gainers Today
Hard-hit stocks led S&P 500 winners. Commodity stocks were the big losers. 
Via Investor's Business Daily
27 Recession-Resistant Stocks To Look At Now
When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not... 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
Pfizer: What Comes After the Covid-19 Fire?
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock. 
Via InvestorPlace
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
7 Cheap Stocks to Buy Now if You Have $100 to Spend
The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks. 
Via InvestorPlace
35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.